The lack of a validated severity scoring system for individuals with Zellweger spectrum disorders (ZSD) hampers optimal patient care and reliable research. Here, we describe the development of such severity score and its validation in a large, well-characterized cohort of ZSD individuals. We developed a severity scoring system based on the 14 organs that typically can be affected in ZSD. A standardized and validated method was used to classify additional care needs in individuals with neurodevelopmental disabilities (Capacity Profile [CAP]). Thirty ZSD patients of varying ages were scored by the severity score and the CAP. The median score was 9 (range 6-19) with a median scoring age of 16.0 years (range 2-36 years). The ZSD severity score was significantly correlated with all 5 domains of the CAP, most significantly with the sensory domain (r = 0.8971, P = <.0001). No correlation was found between age and severity score. Multiple peroxisomal biochemical parameters were significantly correlated with the severity score. The presently reported severity score for ZSD is a suitable tool to assess phenotypic severity in a ZSD patient at any age. This severity score can be used for objective phenotype descriptions, genotype-phenotype correlation studies, the identification of prognostic features in ZSD patients and for classification and stratification of patients in clinical trials.
clinical trials evaluating outcomes of future treatments in ZSD. This urged us to develop a validated severity scoring system for ZSDs.
Here, we describe a severity scoring system for ZSDs and the validation of the score in a large, well-characterized cohort of ZSD patients. The result of the severity score is compared with a validated system that scores additional care needs in individuals with intellectual disabilities (Capacity Profile [CAP]). 5 
| MATERIALS AND METHODS

| Patients
We follow a phenotypically and genetically heterogeneous cohort of ZSD patients at the Academic Medical Centre in Amsterdam. [6] [7] [8] All patients are regularly examined including physical exams and labora- 
| Severity score
A severity scoring system was developed to allow analysis of the severity of the phenotype in individuals with ZSD in a quantitative manner (Table 1) . We defined severity as the severity of consequences of having ZSD for the life of an affected individual. Therefore, both the possible consequences in the prenatal formation of organs and the postnatal functioning of organs are included in this score. We aim to quantify severity irrespective of age, so the score remains stable over time. The ZSD severity score is an organ systembased scoring method existing of 14 different domains that are not interdepending. The assignment of the score (0-2) for each domain is based on multiple variables relevant in ZSD. A domain is scored as 0 if no or no significant abnormality is present; a domain is scored as 1 if a functional disturbance or a minor anomaly is present; a domain is scored as 2 if a severe functional disturbance or a major malformation is present.
All study participants were scored based on personal physical examination by a single trained physician (F.C.C.K.), and on the medical information retrieved from patient records and from interviewing parents. The facial morphology was scored using standard frontal and lateral photographs by a single clinical geneticist (R.C.M.H.) who was blinded for the score results of the other domains. All physical examinations and interviews were done at the same time point as the medical records were collected for evaluation.
| Capacity profile
The CAP is a standardized and validated method for classifying additional care needs in paediatric patients with neurodevelopmental disabilities (Table 2) . 5 The CAP is divided in 5 separate domains of body functions; physical health functions, neuro-musculoskeletal and movement-related functions, sensory functions, mental functions and voice and speech functions according to the frame of reference of the International Classification of Functioning, Disability and Health (ICF, WHO). 9 The intensity of care in each domain is defined from 0 (no need for additional care) to 5 (needs help with every activity). The intensity of additional care in each of the separate domains indicates the CAP for the individual patient. All participants were scored by a single trained physician (F.C.C.K.) using information obtained from parents and from patient records. The CAP was used to determine the correlation between the organ-based ZSD severity score and the additional care needs (care needs over and above the normal age-dependent care) of an individual patient. Furthermore, the CAP allowed investigating the impact of the severity of the phenotype of study participants, as scored by the ZSD severity score, on the various levels of functioning.
| Retrospective data
From the medical records we retrieved information on molecular studies, laboratory results indicating organ functioning, peroxisomal parameters, results of ophthalmological and audiological evaluations, abdominal ultrasounds, MRI of the brain and other medical history data. In all patients, blood collection for biochemical studies was done within 6 months of the scoring time point.
| Statistical analysis
Statistical analyses were performed with GraphPad Prism software for Windows, version 7.02. Comparison of the median severity score between different subgroups was performed using the MannWhitney U test. Correlation analyses were performed using Spearman's correlation test. The Bonferroni-Dunn method was used to correct the significance level thresholds for multiple comparisons.
Detailed information on the statistical tests used for analysis and the related significance level threshold are provided in the figure legends.
3 | RESULTS
| Patient characteristics
The main characteristics of the 30 ZSD patients scored with both the ZSD severity score and CAP, are presented in Table 3 . Twenty-six patients had mutations in PEX1, 2 patients in PEX6, 1 patient in PEX10 and 1 patient in PEX26. Most patients were homozygous for the p.G843D mutation in PEX1, which is the most common mutation among ZSD patients in Western Europe. 10 The study cohort included 
| Scoring results
The median severity score in the present cohort was 9 (range 6-19) ( Figure 1A ). The distribution of the individual severity scores over the 14 different domains is shown in Table 4 . Almost all patients in this cohort (28/30) scored the maximum of 2 points in the domains vision and hearing, but none scored 2 points for the domains oral, gastrointestinal, kidney, limbs or endocrine. All patients had minor oral abnormalities in the form of enamel anomalies (score 1). The male siblings had the same individual severity score, there was 1 point difference in 2 pairs of mixed-gender siblings and 2 points difference in 1 pair of mixed-gender siblings. Eighteen out of 30 patients were 2 Due to limited capacity, amendment of the daily program is necessary. Example: selfcatheterization can be learnt, but this takes more time, so that the daily program must be amended accordingly.
3
As in 2, but personal assistance is needed daily; this can be arranged by appointment. Example: in general, a patient cannot administer his or her own tube-feeding; personal assistance is necessary, and can be arranged at regular times.
4
The physical capacity problems are so great that assistance must be available all day long.
5 24-h surveillance is necessary, for example, via an intercom.
Neuromusculoskeletal and movement-related functions 0 No motor impairments.
1 Slight motor impairments, but no limitations in daily functioning; possibly there is a need for elbow crutches, orthopedic footwear, braces, etc., but no adaptations in the environment.
2
The patient experiences no limitations in daily functioning, but aids and adaptations in the environment are necessary.
3
In spite of aids and adaptations, there are limitations in daily functioning and daily assistance is needed; this can be arranged at regular times.
4
Needs assistance from others all day long, but is actively involved.
5
Is totally dependent on assistance.
Sensory functions 0 No sensory impairments; situations can be assessed age-appropriately.
1 Some sensory impairments. Sometimes aids are needed, but there are no limitations in daily functioning.
2
The individual can function independently without personal assistance, but aids and adaptations in the environment are necessary.
3
In spite of aids and adaptations there are limitations in daily functioning and daily assistance is needed; this can be arranged at regular times. Is totally dependent on assistance.
(Continues)
homozygous for the PEX1 p.G843D mutation. The median severity score in this subgroup of patients was 9 (range 6-15) ( Figure 1B ).
To analyse whether the individual ZSD severity scores correlate with specific clinical characteristics in ZSD, we divided the cohort into subgroups of patients dependent on the presence or absence of various clinical parameters. When comparing patients with and without adrenal insufficiency (excluding the endocrine domain from the overall score in both subgroups), a significant difference (P = .0004) was found between the median ZSD severity score in the group of patients without adrenal insufficiency (n = 21) and the group of patients with adrenal insufficiency (n = 9) ( Figure 1C) . Also, when comparing the patients with and without a percutaneous endoscopic gastrostomy (PEG) tube (excluding the gastrointestinal domain in both subgroups) a significant difference (P = .0013) was found between the median ZSD severity score in the group of patients without a PEG tube (n = 22) and the group of patients with a PEG tube (n = 8) (not shown).
The CAP scores of the present ZSD cohort in each of the 5 different CAP domains is shown in Table 4 . All patients required additional care in at least 3 domains of the CAP. The majority of patients required additional care most markedly in the sensory functions domain and mental functions domain.
| Validation and application
We found no significant correlation between the ZSD severity score and the age of the patients ( Figure 1D) . Similarly, the individual scores in each of the 5 domains of the CAP did not significantly correlate with the age of the ZSD individuals (data not shown). We investigated the relation between the severity score and daily life functioning of each ZSD individual through analysis of the correlation between the ZSD severity score and the different domains of the CAP (Figure 2A-E) . All domains of the CAP were significantly correlated with the severity score, most significantly the sensory functions domain (P = <.0001, correlation coefficient r = 0.8971; Figure 2D ). In 3 Takes initiatives and makes plans which contribute to independent functioning. Mainly has to learn social skills. Needs daily feedback on activities and can be left alone for part of the day. Needs limited support.
4
Needs assistance with every decision; is able to make simple choices, but unable to carry them out. Learns mainly from constant repetition. Needs extensive support.
5
Has no insight into his or her own life, cannot manage his or her own life, and is unable to make decisions or choices; the care-providers know what is needed through observation and experience. Needs pervasive support.
Voice and speech functions 0 The requirements concerning mouth movement ability, vocal tone, breathing, and sensitivity of the oral cavity are met, so that good, understandable speech should be possible. Whether or not the individual actually does talk, and the content of his or her speech depends on the level of mental functioning.
1 As in 0, but vocalization and articulation are difficult, so the listener needs to concentrate more; understanding speech in a telephone conversation is difficult for the listener.
2
The above requirements are met with such difficulty that an augmentative form of communication is needed, but there is no need for assistance from other people.
3
As in 2; the individual is able to use an additional form of communication, but needs assistance installing the device in order to use it.
4
The individual can only communicate if personal assistance is available, for example, because only eye movements are possible. was too small to analyze correlations between different domains of the severity score. As the validation cohort included 4 pairs of siblings, we were able to compare the phenotypic severity between these ZSD siblings, which revealed no major differences in severity between siblings with the same PEX mutation. We separately analyzed the severity scores of patients homozygous for the PEX1 p.
G843D mutation, in order to assess genotype-phenotype correlation in this subgroup of patients by using the ZSD severity score. This showed a similar range in individual severity scores compared with the total group of patients, which underlines the variance in Therefore, interdependence between parameters scored in the CAP and parameters scored in the ZSD severity score seems limited. The CAP was not previously used to validate a disease-specific severity score. In line with the severity score, none of the 5 domains of the CAP correlated significantly with the age of the patients.
The validation cohort of ZSD patients used in this study is genetically heterozygous and, confirmed by the spread in severity scores, phenotypically representing a spectrum of severity. However, it should be noted that no patients with the most severe phenotype (ie, Zellweger syndrome OMIM # 214100) or patients at the mildest end of the spectrum (ie, Heimler syndrome OMIM # 234580) 15 were included in this study. It may be valuable to score larger subgroups of such ZSD patients with the severity score in the future in order to validate the use of this score in these individuals. Most patients in our cohort were known to have mutations in PEX1. Although this is the most commonly affected gene in ZSDs, 10, 16 it could be of value to compare the overall severity scores and domain scores of subgroups of patients with for instance PEX6, PEX10 or PEX26 mutations. This could potentially be achieved by combining data of different ZSD cohorts from multiple countries. Furthermore, we aimed to develop a severity scoring system suitable to quantify phenotypic severity at all ages and thus to remain relatively stable over time. Although the finding that no correlation between the severity score and the age of the patients existed is a first validation of this scoring feature, an additional validation by repeating the scoring procedure in the ZSD patients in this cohort at a later age should be repeated in the future to support this finding. It should be emphasized that although the development of the ZSD severity score is an important first step toward better individual counselling of ZSD patients and their parents, further validation is necessary to assess the value and reliability of the severity score for counselling purposes. Also, when we continue to learn about the natural history of ZSD, some criteria may need to be adjusted for this purpose in the future.
Lastly, all patients were scored by 1 single trained physician to avoid inter-observer variability. However, considering the clear definitions of the individual scoring domains of the ZSD severity score, we believe that this is a robust scoring system not likely to be significantly influenced by inter-observer variability. One limiting factor in this regard could be the scoring of the communication domain, where the presence of (severe) dual sensory impairment can potentially complicate the assessment of communication skills in some individuals.
In conclusion, we developed and validated a severity scoring system for ZSDs. The ZSD severity score can become an important tool in the counselling of parents of ZSD patients, but needs to be further validated for use in the neonatal period and for counselling purposes.
It could be of great added value when classifying and stratifying ZSD patients in clinical trials and when reporting natural history of ZSD patients with a specific genotype. Additionally, the score can be used in the communication with authorities in order to arrange appropriate supportive and financial care for ZSD patients already at an early stage.
